Top

Published in:

12-08-2022 | Care | Review

Plasma exchange in the intensive care unit: a narrative review

Authors: Philippe R. Bauer, Marlies Ostermann, Lene Russell, Chiara Robba, Sascha David, Bruno L. Ferreyro, Joan Cid, Pedro Castro, Nicole P. Juffermans, Luca Montini, Tasneem Pirani, Andry Van De Louw, Nathan Nielsen, Julia Wendon, Anne C. Brignier, Miet Schetz, Jan T. Kielstein, Jeffrey L. Winters, Elie Azoulay, the Nine-I Investigators

Published in: Intensive Care Medicine | Issue 10/2022

Abstract

In this narrative review, we discuss the relevant issues of therapeutic plasma exchange (TPE) in critically ill patients. For many conditions, the optimal indication, device type, frequency, duration, type of replacement fluid and criteria for stopping TPE are uncertain. TPE is a potentially lifesaving but also invasive procedure with risk of adverse events and complications and requires close monitoring by experienced teams. In the intensive care unit (ICU), the indications for TPE can be divided into (1) absolute, well-established, and evidence-based, for which TPE is recognized as first-line therapy, (2) relative, for which TPE is a recognized second-line treatment (alone or combined) and (3) rescue therapy, where TPE is used with a limited or theoretical evidence base. New indications are emerging and ongoing knowledge gaps, notably regarding the use of TPE during critical illness, support the establishment of a TPE registry dedicated to intensive care medicine.

Available only for authorised users

Reeves HM, Winters JL (2014) The mechanisms of action of plasma exchange. Br J Haematol 164:342–351. https://doi.org/10.1111/bjh.12629CrossRefPubMed

Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ (2019) Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher 34:171–354. https://doi.org/10.1002/jca.21705CrossRefPubMed

Abe T, Matsuo H, Abe R, Abe S, Asada H, Ashida A, Baba A, Eguchi K, Eguchi Y, Endo Y, Fujimori Y, Furuichi K, Furukawa Y, Furuya M, Furuya T, Hanafusa N, Hara W, Harada-Shiba M, Hasegawa M, Hattori N, Hattori M, Hidaka S, Hidaka T, Hirayama C, Ikeda S, Imamura H, Inoue K, Ishizuka K, Ishizuka K, Ito T, Iwamoto H, Izaki S, Kagitani M, Kaneko S, Kaneko N, Kanekura T, Kitagawa K, Kusaoi M, Lin Y, Maeda T, Makino H, Makino S, Matsuda K, Matsugane T, Minematsu Y, Mineshima M, Miura K, Miyamoto K, Moriguchi T, Murata M, Naganuma M, Nakae H, Narukawa S, Nohara A, Nomura K, Ochi H, Ohkubo A, Ohtake T, Okada K, Okado T, Okuyama Y, Omokawa S, Oji S, Sakai N, Sakamoto Y, Sasaki S, Sato M, Seishima M, Shiga H, Shimohata H, Sugawara N, Sugimoto K, Suzuki Y, Suzuki M, Tajima T, Takikawa Y, Tanaka S, Taniguchi K, Tsuchida S, Tsukamoto T, Tsushima K, Ueda Y, Wada T, Yamada H, Yamada H, Yamaka T, Yamamoto K, Yokoyama Y, Yoshida N, Yoshioka T, Yamaji K (2021) The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis. Ther Apher Dial 25:728–876. https://doi.org/10.1111/1744-9987.13749CrossRefPubMed

Pham HP, Schwartz J (2019) Therapeutic plasma exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Presse Med 48:338–346. https://doi.org/10.1016/j.lpm.2019.03.016CrossRefPubMed

Chevret S, Hughes RA, Annane D (2017) Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2:CD001798. https://doi.org/10.1002/14651858.CD001798.pub3CrossRefPubMed

Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570–2581. https://doi.org/10.1056/NEJMra1602678CrossRefPubMed

Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76:2017–2023. https://doi.org/10.1212/WNL.0b013e31821e5505CrossRefPubMedPubMedCentral

Naciri Bennani H, Noble J, Chevallier E, Terrec F, Motte L, Giroux-Lathuile C, Bugnazet M, Imerzoukene F, Janbon B, Malvezzi P, Rostaing L, Jouve T (2021) Isoagglutinin removal by plasma centrifugation or filtration (single or double): a prospective study in a single center. J Clin Apher 36:149–160. https://doi.org/10.1002/jca.21857CrossRefPubMed

Yeh JH, Chen WH, Chiu HC (2003) Predicting the course of myasthenic weakness following double filtration plasmapheresis. Acta Neurol Scand 108(3):174–178. https://doi.org/10.1034/j.1600-0404.2003.00107.xCrossRefPubMed

10.

Reverberi R, Reverberi L (2007) Removal kinetics of therapeutic apheresis. Blood Transfus 5:164–174. https://doi.org/10.2450/2007.0032-07CrossRefPubMedPubMedCentral

11.

Ward DM (2011) Conventional apheresis therapies: a review. J Clin Apher 26:230–238. https://doi.org/10.1002/jca.20302CrossRefPubMed

12.

Hafer C, Golla P, Gericke M, Eden G, Beutel G, Schmidt JJ, Schmidt BM, De Reys S, Kielstein JT (2016) Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int Urol Nephrol 48:133–138. https://doi.org/10.1007/s11255-015-1137-3CrossRefPubMed

13.

Stahl K, Bikker R, Seeliger B, Schmidt JJ, Schenk H, Schmidt BMW, Welte T, Haller H, Hoeper MM, Brand K, David S (2021) Effect of therapeutic plasma exchange on immunoglobulin deficiency in early and severe septic shock. J Intensive Care Med 36:1491–1497. https://doi.org/10.1177/0885066620965169CrossRefPubMed

14.

Hafer C, Kielstein JT (2017) Pro: High dose of therapeutic plasma exchange-mind the gap! Nephrol Dial Transplant 32:1457–1460. https://doi.org/10.1093/ndt/gfx084CrossRefPubMed

15.

Schmidt JJ, Asper F, Einecke G, Eden G, Hafer C, Kielstein JT (2018) Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments—a one-year retrospective analysis. BMC Nephrol 19:12. https://doi.org/10.1186/s12882-017-0803-3CrossRefPubMedPubMedCentral

16.

Sharma RR, Saluja K, Jain A, Dhawan HK, Thakral B, Marwaha N (2011) Scope and application of therapeutic apheresis: experience from a tertiary care hospital in North India. Transfus Apher Sci 45:239–245. https://doi.org/10.1016/j.transci.2011.09.002CrossRefPubMed

17.

Islam MB, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD (2017) Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study. Pilot Feasibility Stud 3:40. https://doi.org/10.1186/s40814-017-0185-0CrossRefPubMedPubMedCentral

18.

ERBP Guideline Development Group on Vascular Access, Gatta G (2020) Linee guida di pratica clinica sulla cura peri- e post-operatoria delle fistole e delle protesi arterovenose per emodialisi negli adulti. Sintesi delle raccomandazioni delle "European Renal Best Practice (ERBP)". G Ital Nefrol 37(Suppl 75):S75

19.

Azoulay E, Bauer PR, Mariotte E, Russell L, Knoebl P, Martin-Loeches I, Pène F, Puxty K, Povoa P, Barratt-Due A, Garnacho-Montero J, Wendon J, Munshi L, Benoit D, von Bergwelt-Baildon M, Maggiorini M, Coppo P, Cataland S, Veyradier A, Van de Louw A, Investigators N-i (2019) Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med 45:1518–1539. https://doi.org/10.1007/s00134-019-05736-5CrossRefPubMed

20.

Reimann PM, Mason PD (1990) Plasmapheresis: technique and complications. Intensive Care Med 16:3–10. https://doi.org/10.1007/BF01706318CrossRefPubMed

21.

Cid J, Molina JM, Mustieles MJ, Periáñez M, Lozano M (2015) Comparison of plasma exchange procedures using three apheresis systems. Transfusion 55:1001–1007. https://doi.org/10.1111/trf.12948CrossRefPubMed

22.

Winters JL, Burgstaler EA, Gottschall JL, Balogun RA, Houghton JR, Lee WJ, Snyder EL (2013) A multicenter evaluation of a new therapeutic plasma exchange procedure. Transfusion 53:3269–3278. https://doi.org/10.1111/trf.12189CrossRefPubMed

23.

Burgstaler EA, Pineda AA (2001) Therapeutic plasma exchange: a paired comparison of Fresenius AS104 vs. COBE Spectra J Clin Apher 16:61–66. https://doi.org/10.1002/jca.1014CrossRefPubMed

24.

Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, Goodrich T, Snyder EL (2010) Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion 50:471–477. https://doi.org/10.1111/j.1537-2995.2009.02412.xCrossRefPubMed

25.

Lambert C, Gericke M, Smith R, Hermans C (2011) Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Haemonetics MCS+. J Clin Apher 26:17–22. https://doi.org/10.1002/jca.20271CrossRefPubMed

26.

Kes P, Janssens ME, Bašić-Jukić N, Kljak M (2016) A randomized crossover study comparing membrane and centrifugal therapeutic plasma exchange procedures. Transfusion 56:3065–3072. https://doi.org/10.1111/trf.13850CrossRefPubMed

27.

Ipe TS, Marques MB (2018) Vascular access for therapeutic plasma exchange. Transfusion 58(Suppl 1):580–589. https://doi.org/10.1111/trf.14479CrossRefPubMed

28.

Doggett BM, Session-Augustine N, Roig J, Strunk M, Valiyaparambil S, Sarode R, De Simone N (2019) Single-needle: an effective alternative to dual-needle peripheral access in therapeutic plasma exchange. J Clin Apher 34:21–25. https://doi.org/10.1002/jca.21665CrossRefPubMed

29.

Mustieles MJ, Acosta M, Cid J, Jiménez M, Mateo D, Andreu B, Alba C, Perea D, Lozano M (2020) Peripheral venous access devices for apheresis: 16-gauge is not always needed. Transfusion 60:607–612. https://doi.org/10.1111/trf.15698CrossRefPubMed

30.

Lemaire A, Parquet N, Galicier L, Boutboul D, Bertinchamp R, Malphettes M, Dumas G, Mariotte E, Peraldi MN, Souppart V, Schlemmer B, Azoulay E, Canet E (2017) Plasma exchange in the intensive care unit: Technical aspects and complications. J Clin Apher 32:405–412. https://doi.org/10.1002/jca.21529CrossRefPubMed

31.

Brunetta Gavranić B, Bašić-Jukić N, Premužić V, Kes P (2017) Membrane therapeutic plasma exchange with and without heparin anticoagulation. J Clin Apher 32:479–485. https://doi.org/10.1002/jca.21544CrossRefPubMed

32.

Kissling S, Legallais C, Pruijm M, Teta D, Vogt B, Burnier M, Rondeau E, Ridel C (2017) A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges. BMC Nephrol 18:81. https://doi.org/10.1186/s12882-017-0494-9CrossRefPubMedPubMedCentral

33.

Stegmayr B, Ptak J, Wikström B, Berlin G, Axelsson CG, Griskevicius A, Centoni P, Liumbruno G, Molfettini P, Audzijoniene J, Mokvist K, Sojka BN, Norda R, Knutson F, Ramlow W, Blaha M, Witt V, Evergren M, Tomaz J (2008) World apheresis registry 2003–2007 data. Transfus Apher Sci 39:247–254. https://doi.org/10.1016/j.transci.2008.09.003CrossRefPubMed

34.

Toss F, Edgren G, Berlin G, Stegmayr B, Witt V (2018) Does prophylactic calcium in apheresis cause more harm than good?—Centre heterogeneity within the World Apheresis Association Register prevents firm conclusions. Vox Sang 113:632–638. https://doi.org/10.1111/vox.12698CrossRefPubMed

35.

Kaplan A, Raut P, Totoe G, Morgan S, Zantek ND (2016) Management of systemic unfractionated heparin anticoagulation during therapeutic plasma exchange. J Clin Apher 31:507–515. https://doi.org/10.1002/jca.21441CrossRefPubMed

36.

Tutarel O, Golla P, Beutel G, Bauersachs J, David S, Schmidt BM, Lichtinghagen R, Kielstein JT (2012) Therapeutic plasma exchange decreases levels of routinely used cardiac and inflammatory biomarkers. PLoS ONE 7:e38573. https://doi.org/10.1371/journal.pone.0038573CrossRefPubMedPubMedCentral

37.

Schmidt JJ, Jahn J, Golla P, Hafer C, Kielstein JT, Kielstein H (2015) Effect of therapeutic plasma exchange on plasma levels and total removal of adipokines and inflammatory markers. BMC Obes 2:37. https://doi.org/10.1186/s40608-015-0067-zCrossRefPubMedPubMedCentral

38.

Cid J, Carbassé G, Gamir M, Jiménez M, Arellano-Rodrigo E, Lozano M (2015) Acid-base balance disturbances in plasma exchange depend on the replacement fluid used. Transfusion 55:2653–2658. https://doi.org/10.1111/trf.13215CrossRefPubMed

39.

Flaum MA, Cuneo RA, Appelbaum FR, Deisseroth AB, Engel WK, Gralnick HR (1979) The hemostatic imbalance of plasma-exchange transfusion. Blood 54:694–702CrossRef

40.

Zantek ND, Boral LI, Li Y, Yamada C, Svensson AM, Crane JE, Smith RE, Pagano MB, Rollins-Raval MA, Schmidt AE, Wong ECC, Wu Y (2018) Hemostasis management and therapeutic plasma exchange: results of a practice survey. J Clin Apher 33:604–610. https://doi.org/10.1002/jca.21653CrossRefPubMed

41.

Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N (2001) Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apher 16:134–138. https://doi.org/10.1002/jca.1025CrossRefPubMed

42.

Dzik WH, Kirkley SA (1988) Citrate toxicity during massive blood transfusion. Transfus Med Rev 2:76–94. https://doi.org/10.1016/s0887-7963(88)70035-8CrossRefPubMed

43.

Irani MS, Toushan M, Zhang L, Simpson PM, Karafin MS (2019) Risk of hypotensive reactions is increased when using partial saline replacement for therapeutic plasma exchange. J Clin Apher 34:524–527. https://doi.org/10.1002/jca.21703CrossRefPubMed

44.

Radhakrishnan M, Batra A, Periyavan S, Philip M, Anand V (2018) Hydroxyethyl starch and kidney function: a retrospective study in patients undergoing therapeutic plasma exchange. J Clin Apher 33:278–282. https://doi.org/10.1002/jca.21598CrossRefPubMed

45.

Agreda-Vásquez GP, Espinosa-Poblano I, Sánchez-Guerrero SA, Crespo-Solís E, Cabrera-Vásquez S, López-Salmorán J, Barajas J, Peñaloza-Ramírez P, Tirado-Cárdenas N, Velázquez A (2008) Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective. J Clin Apher 23:163–167. https://doi.org/10.1002/jca.20175CrossRefPubMed

46.

Blasi A, Cid J, Beltran J, Taurà P, Balust J, Lozano M (2016) Coagulation profile after plasma exchange using albumin as a replacement solution measured by thromboelastometry. Vox Sang 110:159–165. https://doi.org/10.1111/vox.12347CrossRefPubMed

47.

Korach JM, Petitpas D, Poiron L, Vincent N, Berger PH, Chillet P, French Registry Study Group (2001) 14 years of therapeutic plasma exchange in France. Transfus Apher Sci 25:73–77. https://doi.org/10.1016/s1473-0502(01)00090-8CrossRefPubMed

48.

Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lämmle B, George JN, Vesely SK (2012) Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion 52:2525–2532. https://doi.org/10.1111/j.1537-2995.2012.03646.xCrossRefPubMedPubMedCentral

49.

Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z (2005) Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 9:391–395. https://doi.org/10.1111/j.1744-9987.2005.00319.xCrossRefPubMed

50.

Couriel D, Weinstein R (1994) Complications of therapeutic plasma exchange: a recent assessment. J Clin Apher 9:1–5. https://doi.org/10.1002/jca.2920090102CrossRefPubMed

51.

Szczeklik W, Wawrzycka K, Włudarczyk A, Sega A, Nowak I, Seczyńska B, Fajfer I, Zając K, Królikowski W, Kózka M (2013) Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther 45:7–13. https://doi.org/10.5603/AIT.2013.0002CrossRefPubMed

52.

Shemin D, Briggs D, Greenan M (2007) Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher 22:270–276. https://doi.org/10.1002/jca.20143CrossRefPubMed

53.

Cheng CW, Hendrickson JE, Tormey CA, Sidhu D (2017) Therapeutic plasma exchange and its impact on drug levels: an ACLPS critical review. Am J Clin Pathol 148:190–198. https://doi.org/10.1093/ajcp/aqx056CrossRefPubMed

54.

McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA (2010) Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 8:1201–1208. https://doi.org/10.1111/j.1538-7836.2010.03818.xCrossRefPubMed

55.

Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ (2007) Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 27:1529–1549. https://doi.org/10.1592/phco.27.11.1529CrossRefPubMed

56.

Krzych ŁJ, Czok M, Putowski Z (2020) Is antimicrobial treatment effective during therapeutic plasma exchange? Investigating the role of possible interactions. Pharmaceutics 12:395. https://doi.org/10.3390/pharmaceutics12050395CrossRefPubMedCentral

57.

Ibrahim RB, Balogun RA (2012) Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose. Semin Dial 25:176–189. https://doi.org/10.1111/j.1525-139X.2011.01030.xCrossRefPubMed

58.

Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, Le Guellec C, Lafont T, Grand A, Rostaing L, Chatelut E, Pourrat J (2013) Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 76:734–740. https://doi.org/10.1111/bcp.12098CrossRefPubMedPubMedCentral

59.

Petitcollin A, Bensalem A, Verdier MC, Tron C, Lemaitre F, Paintaud G, Bellissant E, Ternant D (2020) Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review. Clin Pharmacokinet 59:37–49. https://doi.org/10.1007/s40262-019-00816-7CrossRefPubMed

60.

Peters BJ, Hofer M, Daniels CE, Winters JL (2018) Effect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels. Am J Health Syst Pharm 75:1883–1888. https://doi.org/10.2146/ajhp170885CrossRefPubMed

61.

Kawauchi S, Wada K, Oita A (2019) Changes in blood concentration of mycophenolic acid and FK506 in a heart-transplant patient treated with plasmapheresis. Int J Clin Pharmacol Ther 57:32–36. https://doi.org/10.5414/CP20327CrossRefPubMed

62.

Knaup H, Stahl K, Schmidt BMW, Idowu TO, Busch M, Wiesner O, Welte T, Haller H, Kielstein JT, Hoeper MM, David S (2018) Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care 22:285. https://doi.org/10.1186/s13054-018-2220-9CrossRefPubMedPubMedCentral

63.

Stahl K, Schmidt JJ, Seeliger B, Schmidt BMW, Welte T, Haller H, Hoeper MM, Budde U, Bode C, David S (2020) Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. Crit Care 24:71. https://doi.org/10.1186/s13054-020-2799-5CrossRefPubMedPubMedCentral

64.

David S, Bode C, Putensen C, Welte T, Stahl K, EXCHANGE Study Group (2021) Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med 47:352–354. https://doi.org/10.1007/s00134-020-06339-1CrossRefPubMedPubMedCentral

65.

Memish ZA, Faqihi F, Alharthy A, Alqahtani SA, Karakitsos D (2021) Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives. Int J Antimicrob Agents 57:106273. https://doi.org/10.1016/j.ijantimicag.2020.106273CrossRefPubMed

66.

Fernandez J, Gratacos-Ginès J, Olivas P, Costa M, Nieto S, Mateo D, Sánchez MB, Aguilar F, Bassegoda O, Ruiz P, Caballol B, Pocurull A, Llach J, Mustieles MJ, Cid J, Reverter E, Toapanta ND, Hernández-Tejero M, Martínez JA, Claria J, Fernández C, Mensa J, Arroyo V, Castro P, Lozano M, Covid Clinic Critical Care (CCCC) Group (2020) Plasma exchange: an effective rescue therapy in critically ill patients with coronavirus disease 2019 infection. Crit Care Med 48:e1350–e1355. https://doi.org/10.1097/CCM.0000000000004613CrossRefPubMedPubMedCentral

67.

Doevelaar AAN, Bachmann M, Hölzer B, Seibert FS, Rohn BJ, Bauer F, Witzke O, Dittmer U, Bachmann M, Yilmaz S, Dittmer R, Schneppenheim S, Babel N, Budde U, Westhoff TH (2021) von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019. Crit Care Med 49:e512–e520. https://doi.org/10.1097/CCM.0000000000004918CrossRefPubMed

68.

Faqihi F, Alharthy A, Abdulaziz S, Balhamar A, Alomari A, AlAseri Z, Tamim H, Alqahtani SA, Kutsogiannis DJ, Brindley PG, Karakitsos D, Memish ZA (2021) Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial. Int J Antimicrob Agents 57:106334. https://doi.org/10.1016/j.ijantimicag.2021.106334CrossRefPubMedPubMedCentral

69.

Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M (2021) Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 385:1680–1689. https://doi.org/10.1056/NEJMoa2109908CrossRefPubMed

70.

Dogné S, Flamion B (2020) Endothelial glycocalyx impairment in disease: focus on hyaluronan shedding. Am J Pathol 190:768–780. https://doi.org/10.1016/j.ajpath.2019.11.016CrossRefPubMed

71.

Stahl K, Hillebrand UC, Kiyan Y, Seeliger B, Schmidt JJ, Schenk H, Pape T, Schmidt BMW, Welte T, Hoeper MM, Sauer A, Wygrecka M, Bode C, Wedemeyer H, Haller H, David S (2021) Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. Intensive Care Med Exp 9:57. https://doi.org/10.1186/s40635-021-00417-4CrossRefPubMedPubMedCentral

72.

Hughes RA, Swan AV, van Doorn PA (2014) Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014:CD002063. https://doi.org/10.1002/14651858.CD002063.pub6CrossRefPubMedCentral

73.

Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, Hawley CM, Khalidi N, Floßmann O, Wald R, Girard LP, Levin A, Gregorini G, Harper L, Clark WF, Pagnoux C, Specks U, Smyth L, Tesar V, Ito-Ihara T, de Zoysa JR, Szczeklik W, Flores-Suárez LF, Carette S, Guillevin L, Pusey CD, Casian AL, Brezina B, Mazzetti A, McAlear CA, Broadhurst E, Reidlinger D, Mehta S, Ives N, Jayne DRW, Investigators PEXIVAS (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382:622–631. https://doi.org/10.1056/NEJMoa1803537CrossRefPubMedPubMedCentral

74.

Balogun RA, Sanchez AP, Klingel R, Witt V, Aqui N, Meyer E, Padmanabhan A, Pham HP, Schneiderman J, Schwartz J, Wu Y, Zantek ND, Connelly-Smith L, Dunbar NM (2020) Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA-associated vasculitis. J Clin Apher 35:493–499. https://doi.org/10.1002/jca.21820CrossRefPubMed

75.

Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, Triantafyllou E, Bernal W, Auzinger G, Shawcross D, Eefsen M, Bjerring PN, Clemmesen JO, Hockerstedt K, Frederiksen HJ, Hansen BA, Antoniades CG, Wendon J (2020) High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol 64:69–78. https://doi.org/10.1016/j.jhep.2015.08.018CrossRef

Title: Plasma exchange in the intensive care unit: a narrative review
Authors: Philippe R. Bauer
Marlies Ostermann
Lene Russell
Chiara Robba
Sascha David
Bruno L. Ferreyro
Joan Cid
Pedro Castro
Nicole P. Juffermans
Luca Montini
Tasneem Pirani
Andry Van De Louw
Nathan Nielsen
Julia Wendon
Anne C. Brignier
Miet Schetz
Jan T. Kielstein
Jeffrey L. Winters
Elie Azoulay
the Nine-I Investigators
Publication date: 12-08-2022
Publisher: Springer Berlin Heidelberg
Keyword: Care
Published in: Intensive Care Medicine / Issue 10/2022
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-022-06793-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Plasma exchange in the intensive care unit: a narrative review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2022

Respiratory indications for ECMO: focus on COVID-19

The physiological underpinnings of life-saving respiratory support

Central venous pressure (CVP)

Invasive arterial pressure monitoring: much more than mean arterial pressure!

Phrenic nerve stimulation to protect the diaphragm, lung, and brain during mechanical ventilation

Monitoring cerebral oxygenation in acute brain-injured patients